Form 4 holding
President & Head of R&D
Inhibikase Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 676,564
- Estimated value
- $1,353,128
- Report date
- 21 Feb 2026
- Price
- $2.00
- Ownership
- Direct
Christopher Cabell - President & Head of R&D at Inhibikase Therapeutics, Inc.
Issuer-level insider activity
- Role
- President & Head of R&D
- Issuer ticker
- IKT on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
No buys or sells have been reported by Christopher Cabell since 28 Sep 2025
Reported holdings for Christopher Cabell in Inhibikase Therapeutics, Inc.
Form 4 holding
President & Head of R&D
Inhibikase Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 900,117
- Estimated value
- Report date
- 05 Jan 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for Christopher Cabell in Inhibikase Therapeutics, Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.